Lamotrigine Extended-Release In Elderly Patients With Epilepsy

Completed · Phase 3

Conditions studied: Epilepsy

In brief

This study is being conducted to determine the safety and tolerability of lamotrigine (LTG) in elderly patients with epilepsy. This study will be carried out using an extended-release formulation of lamotrigine (LTG-XR) that will allow once-a-day dosing.

Key facts

Study ID

NCT00516139

Run by

GlaxoSmithKline

People needed

122

Starts

2007-08-01

Expected to finish

2010-07-01

Last updated by the study team

2017-01-18

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confident diagnosis of epilepsy
• Currently treated with one or two antiepileptic medications
• Able to complete a seizure diary

You may not qualify if…

• History of hypersensitivity to lamotrigine
• Progressive diseases that would interfere with the study objectives

Where it is running

• GSK Investigational Site — Gilbert, Arizona, United States
• GSK Investigational Site — Litchfield Park, Arizona, United States
• GSK Investigational Site — Phoenix, Arizona, United States
• GSK Investigational Site — Phoenix, Arizona, United States
• GSK Investigational Site — Fresno, California, United States
• GSK Investigational Site — Fullteron, California, United States
• GSK Investigational Site — Irvine, California, United States
• GSK Investigational Site — Los Angeles, California, United States
• GSK Investigational Site — Pasadena, California, United States
• GSK Investigational Site — Fort Collins, Colorado, United States
• GSK Investigational Site — Newark, Delaware, United States
• GSK Investigational Site — Gainesville, Florida, United States
• GSK Investigational Site — Jacksonville, Florida, United States
• GSK Investigational Site — Jacksonville, Florida, United States
• GSK Investigational Site — Melbourne, Florida, United States
• GSK Investigational Site — Miami, Florida, United States
• GSK Investigational Site — Ponte Vedra Beach, Florida, United States
• GSK Investigational Site — Sarasota, Florida, United States
• GSK Investigational Site — Atlanta, Georgia, United States
• GSK Investigational Site — Atlanta, Georgia, United States
• GSK Investigational Site — Suwanee, Georgia, United States
• GSK Investigational Site — Boise, Idaho, United States
• GSK Investigational Site — Springfield, Illinois, United States
• GSK Investigational Site — Fort Wayne, Indiana, United States
• GSK Investigational Site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.